Analysts Set Dyne Therapeutics, Inc. (NASDAQ:DYN) Target Price at $51.40

Dyne Therapeutics, Inc. (NASDAQ:DYN) has earned a consensus rating of “Buy” from the ten brokerages that are presently covering the firm, MarketBeat reports. Nine investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $51.40.

A number of equities analysts have weighed in on the stock. StockNews.com downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research note on Monday, September 16th. Stifel Nicolaus boosted their target price on Dyne Therapeutics from $41.00 to $66.00 and gave the stock a “buy” rating in a report on Friday, August 16th. Oppenheimer restated an “outperform” rating and set a $55.00 price target on shares of Dyne Therapeutics in a report on Tuesday, September 3rd. HC Wainwright reiterated a “buy” rating and issued a $55.00 price target on shares of Dyne Therapeutics in a research note on Wednesday, September 4th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Dyne Therapeutics from $39.00 to $43.00 and gave the company an “overweight” rating in a research note on Tuesday, July 9th.

Insider Activity

In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of Dyne Therapeutics stock in a transaction that occurred on Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $48,024.50. Following the completion of the sale, the senior vice president now owns 98,568 shares of the company’s stock, valued at approximately $3,405,524.40. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Dyne Therapeutics news, SVP Richard William Scalzo sold 1,390 shares of the firm’s stock in a transaction dated Wednesday, September 18th. The stock was sold at an average price of $34.55, for a total value of $48,024.50. Following the transaction, the senior vice president now directly owns 98,568 shares of the company’s stock, valued at $3,405,524.40. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Oxana Beskrovnaya sold 2,339 shares of the business’s stock in a transaction dated Wednesday, September 18th. The shares were sold at an average price of $34.55, for a total value of $80,812.45. Following the sale, the insider now owns 140,375 shares of the company’s stock, valued at $4,849,956.25. The disclosure for this sale can be found here. Insiders sold 135,304 shares of company stock valued at $4,857,019 over the last three months. Insiders own 20.77% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in DYN. Concurrent Investment Advisors LLC bought a new stake in shares of Dyne Therapeutics during the 1st quarter valued at $573,000. Sei Investments Co. purchased a new stake in Dyne Therapeutics in the first quarter worth about $693,000. Rafferty Asset Management LLC increased its position in Dyne Therapeutics by 17.7% in the fourth quarter. Rafferty Asset Management LLC now owns 164,041 shares of the company’s stock worth $2,182,000 after buying an additional 24,632 shares in the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Dyne Therapeutics in the first quarter worth about $810,000. Finally, Commodore Capital LP purchased a new position in shares of Dyne Therapeutics during the 4th quarter valued at about $11,970,000. 96.68% of the stock is currently owned by institutional investors.

Dyne Therapeutics Stock Down 2.3 %

Shares of DYN stock opened at $33.83 on Friday. The stock has a market cap of $2.96 billion, a price-to-earnings ratio of -8.52 and a beta of 1.07. The business’s fifty day moving average is $40.26 and its 200 day moving average is $33.84. Dyne Therapeutics has a twelve month low of $6.40 and a twelve month high of $47.45.

Dyne Therapeutics (NASDAQ:DYN) last released its earnings results on Monday, August 12th. The company reported ($0.70) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.02. Equities research analysts expect that Dyne Therapeutics will post -2.96 earnings per share for the current fiscal year.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.